Literature DB >> 25921402

Small-molecule MDM2-p53 inhibitors: recent advances.

Bian Zhang1, Bernard T Golding, Ian R Hardcastle.   

Abstract

Potent and selective small-molecule inhibitors of the p53-MDM2 interaction intended for the treatment of p53 wild-type tumors have been designed and optimized in a number of chemical series. This review details recent disclosures of compounds in advanced optimization and features key series that have given rise to clinical trial candidates. The structure-activity relationships for inhibitor classes are discussed with reference to x-ray structures, and common structural features are identified.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25921402     DOI： 10.4155/fmc.15.13

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


  16 in total

1.  Dysfunction of the MDM2/p53 axis is linked to premature aging.

Authors:  Davor Lessel; Danyi Wu; Carlos Trujillo; Thomas Ramezani; Ivana Lessel; Mohammad K Alwasiyah; Bidisha Saha; Fuki M Hisama; Katrin Rading; Ingrid Goebel; Petra Schütz; Günter Speit; Josef Högel; Holger Thiele; Gudrun Nürnberg; Peter Nürnberg; Matthias Hammerschmidt; Yan Zhu; David R Tong; Chen Katz; George M Martin; Junko Oshima; Carol Prives; Christian Kubisch
Journal:  J Clin Invest       Date:  2017-08-28       Impact factor: 14.808

Review 2.  A patent review of the ubiquitin ligase system: 2015-2018.

Authors:  Xin Li; Ekinci Elmira; Sagar Rohondia; Jicang Wang; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2018-11-23       Impact factor: 6.674

Review 3.  Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

Authors:  Faiz Anwer; Kevin Mathew Gee; Ahmad Iftikhar; Mirza Baig; Atlantis Dawn Russ; Sabina Saeed; Muhammad Abu Zar; Faryal Razzaq; Jennifer Carew; Steffan Nawrocki; Hussam Al-Kateb; Nadia Nunes Cavalcante Parr; Ali McBride; Jason Valent; Christy Samaras
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-03-25

4.  Destabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategy.

Authors:  Usama Ashraf; Laura Tengo; Laurent Le Corre; Guillaume Fournier; Patricia Busca; Andrew A McCarthy; Marie-Anne Rameix-Welti; Christine Gravier-Pelletier; Rob W H Ruigrok; Yves Jacob; Pierre-Olivier Vidalain; Nicolas Pietrancosta; Thibaut Crépin; Nadia Naffakh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-10       Impact factor: 11.205

5.  PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.

Authors:  Xin Han; Wenyi Wei; Yi Sun
Journal:  Acta Mater Med       Date:  2022-05-31

Review 6.  Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways.

Authors:  Dariusz Stępiński
Journal:  Histochem Cell Biol       Date:  2016-05-03       Impact factor: 4.304

Review 7.  Ubiquitin ligases in oncogenic transformation and cancer therapy.

Authors:  Daniela Senft; Jianfei Qi; Ze'ev A Ronai
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

8.  Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.

Authors:  Mahadev Rao; Scott M Atay; Vivek Shukla; Young Hong; Trevor Upham; R Taylor Ripley; Julie A Hong; Mary Zhang; Emily Reardon; Patricia Fetsch; Markku Miettinen; Xinmin Li; Cody J Peer; Tristan Sissung; William D Figg; Assunta De Rienzo; Raphael Bueno; David S Schrump
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

9.  Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis.

Authors:  Olga Fedorova; Alexandra Daks; Varvara Petrova; Alexey Petukhov; Larissa Lezina; Oleg Shuvalov; Pavel Davidovich; Darya Kriger; Ekaterina Lomert; Dmitry Tentler; Victor Kartsev; Burhan Uyanik; Vyacheslav Tribulovich; Oleg Demidov; Gerry Melino; Nickolai A Barlev
Journal:  Cell Cycle       Date:  2018-09-05       Impact factor: 4.534

Review 10.  Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

Authors:  E T Aristizabal Prada; C J Auernhammer
Journal:  Endocr Connect       Date:  2017-11-16       Impact factor: 3.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.